Cessation of Nucleos(t)ide Analogue treatment after HBeAg seroconversion is associated with a 4-fold increased risk of relapse in cirrhotic compared to non-cirrhotic patients

S. Van Hees,Stefan Bourgeois,H. Van Vlierberghe,Thomas Sersté,Sven Francque,P. Michielsen,D. Sprengers,Herwig Reynaert,Jean Henrion,S Negrin Dastis,Jean Delwaide,Luc Lasser,Jochen Decaestecker,H Orlent,F Janssens,Geert Robaeys,Isabelle Colle,P Starkel,Christophe Moreno,F Nevens,T. Vanwolleghem

Cessation of Nucleos(t)ide Analogue treatment after HBeAg seroconversion is associated with a 4-fold increased risk of relapse in cirrhotic compared to non-cirrhotic patients

2017

Isabelle Colle - Consulting: Promethera; Grant/Research Support: abbvie; Patent Held/Filed: Trombogenics; Speaking and Teaching: BMS Christophe Moreno - Consulting: Abbvie, Janssen, Gilead, BMS, MSD; Grant/Research Support: Janssen, Gilead, Roche, Astellas, Abbvie Frederik Nevens - Consulting: MSD, CAF, Intercept, Gore, BMS, Abbvie, Novartis, Durect, Janssens-Cilag, Ono Pharma, Promethera Biosciences, Gilead; Grant/Research Support: Ferring, Roche, Astellas, Novartis, Janssen-Cilag, Abbvie, Gilead

Keywords:

Biology
HBeAg
Virology
Seroconversion
increased risk
hbeag seroconversion

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations